Literature DB >> 18805575

Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery.

Laura Palma1, Victoria Marcus, Lucy Gilbert, George Chong, William D Foulkes.   

Abstract

BACKGROUND: Women with Lynch syndrome have a 40 to 60% lifetime risk of endometrial cancer and a 10 to 12% lifetime risk of ovarian cancer and may consider prophylactic gynecological surgery as an option for risk reduction. CASE: We report a case of synchronous primary cancers of the endometrium and fallopian tube diagnosed at time of prophylactic surgery in an MSH2 mutation carrier.
CONCLUSION: Risk-reducing gynecological surgery in Lynch syndrome must include complete removal of the fallopian tubes in addition to the ovaries and endometrium, followed by careful pathological review. Prospective studies are needed to clarify the incidence of occult primary carcinoma of the fallopian tube among female MMR mutation carriers undergoing prophylactic surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805575     DOI: 10.1016/j.ygyno.2008.08.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Authors:  Murray Joseph Casey; Chhanda Bewtra; Henry T Lynch; Carrie Snyder; Mark Stacy; Patrice Watson
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

2.  Systemic Sclerosis and Multiple Cancers of the Female Genital Tract: Prolonged Survival following Current Treatment Strategies.

Authors:  Georgios Androutsopoulos; Georgios Adonakis; Athanasios Tsamandas; Andreas Andonopoulos; Georgios Decavalas
Journal:  Case Rep Rheumatol       Date:  2012-01-04

3.  Ovarian carcinoma in situ of presumable fallopian tube origin in a patient with Lynch syndrome: A case report.

Authors:  Kayo Inoue; Hiroshi Tsubamoto; Hiroyuki Hao; Kazuo Tamura; Tomoko Hashimoto-Tamaoki
Journal:  Gynecol Oncol Case Rep       Date:  2013-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.